Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: DaveAu who wrote (8830)	2/17/2002 5:33:30 PM
From: axial	Read Replies (1) \| Respond to of 14101

Hi, Dave - Nice to see your post! I agree. Reading the never-ending repetition of negativity was wearing: there was no recognition of any other possibilities. Thanks for your summary of what is a string of impressive accomplishments that are collaborative in nature. Not 20 seconds ago, I posted the following in a PM... ( Some have called this "Jim, beating the drum..." ) >smile<. "...I'm sure you know that I attach great significance to WF10, and what I call the possible imminent "change in perception" on DMX. If (as we both suspect) WF10 P3 comes in strong (and REK's moves certainly confirm that inference) then REK and DMX are going to be the Cinderella story of the year. (...Rebecca's Valentine is now passé) >g< Anyway, enough. It's amazing how the endless string of verbiage, and posts causes our thinking to get lost: what follows is what I have always believed, at heart - and makes me think we are not far apart in our thinking..." Message 16904377 Best regards, Jim

To: DaveAu who wrote (8830)	2/17/2002 10:22:36 PM
From: David Graham	Read Replies (1) \| Respond to of 14101

Dave, I've given up worrying about Bay Street research coverage, its too oriented to retail investors and what we need to make serious money is institutions buying big chunks of this and holding it. Unfortunately, the kind of retail investor that gets tuned into a stock by a brokerage report will sell as easily as they buy. They don't always lead to long-term price appreciation. For a smaller company, and DMX is tiny, the most we could expect is a couple of weeks of interest from a brokerage as the brokers touted the stock to their clients. And we all know only too well why that won't happen. On that note, am I the only one who has noticed that REK has avoided paying underwriting fees to even second-tier firms like Yorktown but is giving an 8% cut to a short seller calling themselves a venture capitalist? Seriously, the more I think about it, the less sense it makes. What's her deal? At least we might have gotten a quick write-up from a broker (I'm assuming that REK learned her lesson from the last fiasco). [BTW - I never congratulated those of you who sniffed out the fact that Acqua aren't venture capitalists - and if anyone's in doubt, this is NOT how VCs work.] I might be sounding grumpy, but I'm not down on the company at this point, however, I do have real questions about the Acqua deal (and historically weak management). The good news is that now that FDA approval looks like it might happen in my lifetime, then DMX may post some material sales data (as the UK is waste of time so far). Actual cash flow will likely draw the attention of institutions, as it will give them something to model (maybe the can ask Wolf for tips!) and we might get some brand name investors. If this happens soon enough, DMX might not get booted out of the S&P/TSE Composite Index (if DMX goes, it will likely be in the third wave of deletions scheduled for December). I have questions for anyone with the time/inclination to respond: What's the likelihood that the patent will be extended in the various markets? Also, I'm not clear on where they are with WF10 trials, can anyone explain that? What's the status of the toe fungus project?